AstraZeneca said on Monday that its experimental drug tozorakimab achieved a “meaningful reduction” in moderate-to-severe flare-ups of chronic obstructive pulmonary disease in a late-stage trial, building on positive results reported last month.
The drug met the primary endpoint in the “MIRANDA” study, showing a statistically significant and clinically meaningful decrease in the annualized rate of moderate-to-severe COPD exacerbations in both current and former smokers.
Read Also – Rat poison discovered in HiPP baby food jar in Austria
Patients who continued to experience moderate-to-severe exacerbations despite standard inhaled therapy were given either 300 mg of tozorakimab or a placebo every two weeks, in addition to their ongoing treatment during the study.
The latest results further strengthen investor expectations for the drug’s potential, coming after tozorakimab met the primary endpoints in two other late-stage trials in March, where it also demonstrated a reduction in COPD flare-ups.
